Delving into the Latest Updates on HS-20118 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

HS-20118

Target-

Action-

Mechanism-

Therapeutic Areas

Immune System DiseasesInfectious DiseasesSkin and Musculoskeletal Diseases

Active Indication

Chronic large plaque psoriasisArthritis, PsoriaticPlaque psoriasis

Inactive Indication-

Originator Organization

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active Organization

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The study will be conducted in 2 parts (SAD and FE for Part 1 and MAD for Part2).
Part 1 is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability, immunogenicity, and PK of HS-20118 and explore the food effect and fasting time on PK after a single oral dose in healthy participants.
Part 2 is a multi-center, randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability, immunogenicity, PK, and PD of HS-20118 after multiple oral doses in patients with moderate to severe plaque psoriasis.

Start Date16 May 2025

Sponsor / Collaborator

Jiangsu Hansoh Pharmaceutical Co., Ltd.

NCT06846710

/ RecruitingPhase 1

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of HS-20118 in Adult Participants

The study will be conducted in 2 parts (SAD for Part 1 and MAD for Part2). Part 1 is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability, immunogenicity, and PK of HS-20118 after a single oral dose in healthy participants.
Part 2 is a multi-center, randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability, immunogenicity, PK, and PD of HS-20118 after multiple oral doses in patients with moderate to severe plaque psoriasis .

Start Date02 May 2025

Sponsor / Collaborator

Jiangsu Hansoh Pharmaceutical Co., Ltd.

100 Clinical Results associated with HS-20118

Login to view more data

100 Translational Medicine associated with HS-20118

Login to view more data

100 Patents (Medical) associated with HS-20118

Login to view more data

100 Deals associated with HS-20118

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic large plaque psoriasis	Phase 1	China	Jiangsu Hansoh Pharmaceutical Co., Ltd.	16 May 2025
Arthritis, Psoriatic	Phase 1	United States	Jiangsu Hansoh Pharmaceutical Co., Ltd.	02 May 2025
Arthritis, Psoriatic	Phase 1	New Zealand	Jiangsu Hansoh Pharmaceutical Co., Ltd.	02 May 2025
Plaque psoriasis	Phase 1	United States	Jiangsu Hansoh Pharmaceutical Co., Ltd.	02 May 2025
Plaque psoriasis	Phase 1	New Zealand	Jiangsu Hansoh Pharmaceutical Co., Ltd.	02 May 2025